Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. / Malani, Disha; Kumar, Ashwini; Brück, Oscar; Kontro, Mika; Yadav, Bhagwan; Hellesøy, Monica; Kuusanmäki, Heikki; Dufva, Olli; Kankainen, Matti; Eldfors, Samuli; Potdar, Swapnil; Saarela, Jani; Turunen, Laura; Parsons, Alun; Västrik, Imre; Kivinen, Katja; Saarela, Janna; Räty, Riikka; Lehto, Minna; Wolf, Maija; Gjertsen, Bjorn Tore; Mustjoki, Satu; Aittokallio, Tero; Wennerberg, Krister; Heckman, Caroline A.; Kallioniemi, Olli; Porkka, Kimmo.

In: Cancer Discovery, Vol. 12, No. 2, 2022, p. 388-401.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Malani, D, Kumar, A, Brück, O, Kontro, M, Yadav, B, Hellesøy, M, Kuusanmäki, H, Dufva, O, Kankainen, M, Eldfors, S, Potdar, S, Saarela, J, Turunen, L, Parsons, A, Västrik, I, Kivinen, K, Saarela, J, Räty, R, Lehto, M, Wolf, M, Gjertsen, BT, Mustjoki, S, Aittokallio, T, Wennerberg, K, Heckman, CA, Kallioniemi, O & Porkka, K 2022, 'Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia', Cancer Discovery, vol. 12, no. 2, pp. 388-401. https://doi.org/10.1158/2159-8290.CD-21-0410

APA

Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., Potdar, S., Saarela, J., Turunen, L., Parsons, A., Västrik, I., Kivinen, K., Saarela, J., Räty, R., Lehto, M., ... Porkka, K. (2022). Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 12(2), 388-401. https://doi.org/10.1158/2159-8290.CD-21-0410

Vancouver

Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery. 2022;12(2):388-401. https://doi.org/10.1158/2159-8290.CD-21-0410

Author

Malani, Disha ; Kumar, Ashwini ; Brück, Oscar ; Kontro, Mika ; Yadav, Bhagwan ; Hellesøy, Monica ; Kuusanmäki, Heikki ; Dufva, Olli ; Kankainen, Matti ; Eldfors, Samuli ; Potdar, Swapnil ; Saarela, Jani ; Turunen, Laura ; Parsons, Alun ; Västrik, Imre ; Kivinen, Katja ; Saarela, Janna ; Räty, Riikka ; Lehto, Minna ; Wolf, Maija ; Gjertsen, Bjorn Tore ; Mustjoki, Satu ; Aittokallio, Tero ; Wennerberg, Krister ; Heckman, Caroline A. ; Kallioniemi, Olli ; Porkka, Kimmo. / Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. In: Cancer Discovery. 2022 ; Vol. 12, No. 2. pp. 388-401.

Bibtex

@article{b63de20d3f634856bc3ce812ed592c81,
title = "Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia",
abstract = "We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommen-dations, providing a paradigm for individualized implementation of functional precision cancer medicine.",
author = "Disha Malani and Ashwini Kumar and Oscar Br{\"u}ck and Mika Kontro and Bhagwan Yadav and Monica Helles{\o}y and Heikki Kuusanm{\"a}ki and Olli Dufva and Matti Kankainen and Samuli Eldfors and Swapnil Potdar and Jani Saarela and Laura Turunen and Alun Parsons and Imre V{\"a}strik and Katja Kivinen and Janna Saarela and Riikka R{\"a}ty and Minna Lehto and Maija Wolf and Gjertsen, {Bjorn Tore} and Satu Mustjoki and Tero Aittokallio and Krister Wennerberg and Heckman, {Caroline A.} and Olli Kallioniemi and Kimmo Porkka",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors; Published by the American Association for Cancer Research.",
year = "2022",
doi = "10.1158/2159-8290.CD-21-0410",
language = "English",
volume = "12",
pages = "388--401",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research",
number = "2",

}

RIS

TY - JOUR

T1 - Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

AU - Malani, Disha

AU - Kumar, Ashwini

AU - Brück, Oscar

AU - Kontro, Mika

AU - Yadav, Bhagwan

AU - Hellesøy, Monica

AU - Kuusanmäki, Heikki

AU - Dufva, Olli

AU - Kankainen, Matti

AU - Eldfors, Samuli

AU - Potdar, Swapnil

AU - Saarela, Jani

AU - Turunen, Laura

AU - Parsons, Alun

AU - Västrik, Imre

AU - Kivinen, Katja

AU - Saarela, Janna

AU - Räty, Riikka

AU - Lehto, Minna

AU - Wolf, Maija

AU - Gjertsen, Bjorn Tore

AU - Mustjoki, Satu

AU - Aittokallio, Tero

AU - Wennerberg, Krister

AU - Heckman, Caroline A.

AU - Kallioniemi, Olli

AU - Porkka, Kimmo

N1 - Publisher Copyright: © 2021 The Authors; Published by the American Association for Cancer Research.

PY - 2022

Y1 - 2022

N2 - We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommen-dations, providing a paradigm for individualized implementation of functional precision cancer medicine.

AB - We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommen-dations, providing a paradigm for individualized implementation of functional precision cancer medicine.

U2 - 10.1158/2159-8290.CD-21-0410

DO - 10.1158/2159-8290.CD-21-0410

M3 - Journal article

C2 - 34789538

AN - SCOPUS:85124440906

VL - 12

SP - 388

EP - 401

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 2

ER -

ID: 298119708